[go: up one dir, main page]

BR0117063A - Uso de ciclopamina no tratamento de carcinoma de células basais e outros tumores - Google Patents

Uso de ciclopamina no tratamento de carcinoma de células basais e outros tumores

Info

Publication number
BR0117063A
BR0117063A BR0117063-5A BR0117063A BR0117063A BR 0117063 A BR0117063 A BR 0117063A BR 0117063 A BR0117063 A BR 0117063A BR 0117063 A BR0117063 A BR 0117063A
Authority
BR
Brazil
Prior art keywords
cyclopamine
tumors
cell carcinoma
basal cell
tumor
Prior art date
Application number
BR0117063-5A
Other languages
English (en)
Inventor
Sinan Tas
Oktay Avci
Original Assignee
Sinan Tas
Oktay Avci
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21619326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0117063(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sinan Tas, Oktay Avci filed Critical Sinan Tas
Publication of BR0117063A publication Critical patent/BR0117063A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"USO DE CICLOPAMINA NO TRATAMENTO DE CARCINOMA DE CéLULAS BASAIS E OUTROS TUMORES". Esta invenção refere-se ao uso de ciclopamina in vivo em Carcinomas de células basais, para atingir efeito terapêutico por causar a diferenciação das células tumorosas, e ao mesmo tempo, a morte apoptótica e a remoção altamente eficientes destas células tumorosas, e ao mesmo tempo, conservando as células teciduais normais, inclusive as células indiferenciadas da camada basal epidérmica normal e os folículos pilosos. Causar apoptose por ciclopamina é por um mecanismo não-genotóxico. Estes efeitos tornam o uso de ciclopamina altamente desejável no tratamento de Carcinomas de células basais e outros tumores que usam a via de transdução de sinais hedgehog/abrandada para a proliferação e prevenção de apoptose.
BR0117063-5A 2001-07-02 2001-07-02 Uso de ciclopamina no tratamento de carcinoma de células basais e outros tumores BR0117063A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2001/000027 WO2002078703A1 (en) 2001-07-02 2001-07-02 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors

Publications (1)

Publication Number Publication Date
BR0117063A true BR0117063A (pt) 2004-07-27

Family

ID=21619326

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0117063-5A BR0117063A (pt) 2001-07-02 2001-07-02 Uso de ciclopamina no tratamento de carcinoma de células basais e outros tumores

Country Status (14)

Country Link
EP (4) EP1561464A3 (pt)
JP (3) JP2004536045A (pt)
KR (1) KR20090125833A (pt)
CN (2) CN1525859B (pt)
AT (2) ATE305300T1 (pt)
AU (1) AU2001272892B8 (pt)
BR (1) BR0117063A (pt)
CA (1) CA2452151C (pt)
DE (2) DE60113733T2 (pt)
DK (2) DK1401438T3 (pt)
ES (3) ES2534400T3 (pt)
PT (1) PT1411938E (pt)
RU (1) RU2312661C2 (pt)
WO (2) WO2002078703A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
EP1411938B1 (en) * 2001-07-02 2005-07-06 Tas, Sinan Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis
EP1561464A3 (en) * 2001-07-02 2007-04-25 Sinan Tas Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
US20170326118A1 (en) 2001-07-02 2017-11-16 Sinan Tas Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells
CA2619889C (en) * 2005-08-22 2020-05-05 The Johns Hopkins University Use of itraconazole and salts thereof for treating cancer
DK1978993T3 (en) 2005-10-31 2017-03-20 Oncomed Pharm Inc Compositions and Methods for Treating Cancer Based on Human FZD Receptors
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
KR101563010B1 (ko) * 2006-10-31 2015-10-26 더 가버먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤 휴먼 서비씨즈 평활화 폴리펩티드 및 사용 방법
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
EP2106439B1 (en) 2007-01-24 2014-11-12 The Regents of the University of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
NZ579356A (en) * 2007-03-07 2012-04-27 Infinity Pharmaceuticals Inc Cyclopamine lactam analogs and methods of use thereof
AU2008223355B2 (en) 2007-03-07 2014-03-20 Infinity Discovery, Inc. Heterocyclic cyclopamine analogs and methods of use thereof
EP2224807B1 (en) 2007-12-27 2016-11-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
WO2009099625A2 (en) * 2008-02-08 2009-08-13 The Board Of Regents Of The University Of Texas System Cyclopamine tartrate salt and uses thereof
MX2011003183A (es) 2008-09-26 2011-04-21 Oncomed Pharm Inc Agentes que se unen a receptor encrespado y usos de los mismos.
WO2010080817A2 (en) * 2009-01-06 2010-07-15 Utah State University Carbohydrate-cyclopamine conjugates as anticancer agents
JP2009143963A (ja) * 2009-03-25 2009-07-02 Sinan Tas 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物
JP6141015B2 (ja) 2009-08-05 2017-06-07 インフィニティ ファーマスーティカルズ、インク． シクロパミン類似体の酵素によるアミノ基転移
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
JP2015536933A (ja) 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路結合剤を用いて神経内分泌腫瘍を処置する方法
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
WO2015096654A1 (zh) * 2013-12-26 2015-07-02 中国科学院上海生命科学研究院 Shh信号通路特异性抑制剂的应用
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
US20170231968A1 (en) * 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
CN117940170A (zh) 2021-09-13 2024-04-26 辛南·塔斯 有效干预人类衰老和衰老疾病及其效果
CN114292279B (zh) * 2022-01-07 2023-05-09 吉林省农业科学院 一种藜芦抗癌有效成分环杷明提取与分离方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851993A (en) * 1994-06-13 1998-12-22 Biotie Therapies Ltd. Suppression of tumor cell growth by syndecan-1 ectodomain
EP1067939B1 (en) * 1998-04-09 2015-09-16 The Johns Hopkins University Use of steroidal alkaloid derivatives as inhibitors of hedgehog protein signaling pathways
DE69942342D1 (de) * 1998-09-23 2010-06-17 Res Dev Foundation Tocopherole, tocotrienole, sonstige chroman- und seitenkettenderivate, sowie deren verwendungen
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
ATE283700T1 (de) * 1999-06-08 2004-12-15 Lorantis Ltd Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges
JP5420128B2 (ja) * 1999-10-13 2014-02-19 ジョンズ ホプキンス ユニバーシティ スクール オブ メディシン ヘッジホッグ経路の調節物質、並びにそれに関する組成物及び利用法
AU1935801A (en) * 1999-11-30 2001-06-12 Curis, Inc. Methods and compositions for regulating lymphocyte activity
CU23175A1 (es) * 2000-07-17 2006-09-22 Ct De Investigacion Y Desarrol Formulacion liposomica de propionato de clobetasol
EP1411938B1 (en) * 2001-07-02 2005-07-06 Tas, Sinan Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis
EP1561464A3 (en) * 2001-07-02 2007-04-25 Sinan Tas Use of cyclopamine in the treatment of basal cell carcinoma and other tumors

Also Published As

Publication number Publication date
JP2014028834A (ja) 2014-02-13
CN1522146A (zh) 2004-08-18
EP1561464A2 (en) 2005-08-10
ATE299022T1 (de) 2005-07-15
DK1401438T3 (da) 2006-02-13
EP2216022B1 (en) 2015-01-07
WO2002078704A1 (en) 2002-10-10
WO2002078703A8 (en) 2003-06-12
CN1525859B (zh) 2010-05-05
EP1561464A3 (en) 2007-04-25
WO2002078703A1 (en) 2002-10-10
EP2216022A1 (en) 2010-08-11
PT1411938E (pt) 2005-11-30
ES2250434T3 (es) 2006-04-16
CA2452151C (en) 2012-01-03
DE60204966D1 (de) 2005-08-11
JP2010132691A (ja) 2010-06-17
DE60204966T2 (de) 2006-05-18
EP1401438B1 (en) 2005-09-28
CA2452151A1 (en) 2002-10-10
JP5424923B2 (ja) 2014-02-26
RU2004103074A (ru) 2005-05-10
EP1401438A1 (en) 2004-03-31
EP2862570A1 (en) 2015-04-22
KR20090125833A (ko) 2009-12-07
JP2004536045A (ja) 2004-12-02
DE60113733T2 (de) 2006-06-29
RU2312661C2 (ru) 2007-12-20
AU2001272892B2 (en) 2006-03-16
ES2246011T3 (es) 2006-02-01
ATE305300T1 (de) 2005-10-15
CN1525859A (zh) 2004-09-01
AU2001272892B8 (en) 2006-05-04
ES2534400T3 (es) 2015-04-22
CN1230169C (zh) 2005-12-07
DK1411938T3 (da) 2005-11-07
DE60113733D1 (de) 2006-02-09

Similar Documents

Publication Publication Date Title
BR0117063A (pt) Uso de ciclopamina no tratamento de carcinoma de células basais e outros tumores
HU0102039D0 (en) Use of paclitaxel stabilized with albumin for the preparation of pharmaceutical compositions treating solid tumors and the pharmaceutical compositions obtained thereby
NZ544472A (en) Compounds and therapeutical use thereof
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
PT1202722E (pt) Usos para o tratamento ou prevencao de disturbios do sono usando doses muito baixas de ciclobenzaprina
ATE430570T1 (de) Synergistische kombinationstherapie zur krebsbehandlung
BR0115162A (pt) Tratamentos antitumorais eficazes
DE60124387D1 (de) Synergistische kombination zur behandlung von kolorektalkarzinom
DE60228544D1 (de) Triptolid-prodrugs zur krebstherapie
DE60141194D1 (de) Behandlung des metastasierenden Karzinoms der Niere
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
IL155237A0 (en) Combination therapy for the treatment of estrogen-sensitive disease
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
WO2000037065A3 (en) Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs
ZA200209835B (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or anti-metabolites.
MY136408A (en) Active substance combinations and therapies for treating abuse of alcohol
IL156144A0 (en) Novel therapeutic use of a thienylcyclohexylamine derivative
UY29136A1 (es) Uso de epotilonas en el tratamiento de metastasis osea
ATE362480T1 (de) Phenanthridinderivate und phenanthridin enthaltende antitumorale arzneimittel
DK1385497T3 (da) Forebyggelse eller behandling af bryst-, prostata- og/eller halscancer med N,N-dimethylglycin

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SINAN TAS (TR)

Free format text: TRANSFERIDO DE: OKTAY AVCI

B25G Requested change of headquarter approved

Owner name: SINAN TAS (TR)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020060181175/RJ DE 05/12/2006.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]